Dr Ashanya (Ash) Malalasekera | Chris O'Brien Lifehouse
Dr Ashanya (Ash) MalalasekeraMedical Oncologist, Survivorship Specialist

    Dr Ashanya (Ash) Malalasekera

    Survivorship Specialist, Medical Oncologist

    FRACP, PhD

    Available days: Every Friday (first Friday of the month face-to-face, otherwise via Telehealth)

    CONTACT:

    Referral contact: Maria Sabogal Nova (patient navigator)

    Phone: 02 8514 0636

    Email: supportivecarereferrals@lh.org.au

    Ash is a medical oncologist and early career clinician researcher based in Sydney and South Western Sydney Local Health Districts. She has more than eight years experience specialising in the care of people diagnosed with breast, gynaecological, colorectal and lung cancers, from diagnosis to extended survivorship. She is a 2019 IASLC Young Investigator Grant recipient for research in Cancer-Related Fatigue and a 2020 CINSW Innovations Grant recipient for research directed at equity of survivorship care for multicultural communities.  Her focus at Chris O’Brien Lifehouse is to complement standard medical oncology care with an evidence-based approach to screening for and anticipating residual and long-term toxicities, surveillance, MDT service access and individualised care plans.

    • Senior Clinical Lecturer, University of Sydney
    • Survivorship Research Group, COSA, PC4, IASLC, MOGA, PACCSC.
    • Steering committees: 2021 LFA LUCAS Working Group, 2018 Cancer Australia Optimal Care Pathways Project Steering Committee, 2019 ‘RE-ENGAGE’ Pilot study in Childhood Cancer Survivors, 2019 Cancer Australia exemplar care and referral pathway for breast cancer care.

    TIMES TO DIAGNOSIS AND TREATMENT OF LUNG CANCER IN NSW, AUSTRALIA: A MULTI-CENTRE, MEDICARE DATA-LINKAGE STUDY
    A Malalasekera, P Blinman, H Dhillon, N Stefanic, P Grimison, A Jain, M D’Souza, S Kao, J Vardy. Journal of Oncology Practice 2018 14:10

    DELAYS TO DIAGNOSIS AND TREATMENT OF PEOPLE WITH LUNG CANCER IN AUSTRALIA: HEALTH CARE PROFESSIONAL PERCEPTIONS OF ACTUAL VERSUS ACCEPTABLE TIMEFRAMES
    A Malalasekera, H Dhillon, P Blinman, S Kao, J Vardy. Internal Medicine Journal 2018 SEP; 48(9):1063-1071

    HOW LONG IS TOO LONG? A SCOPING REVIEW OF HEALTH SYSTEM DELAYS IN LUNG CANCER
    A Malalasekera, S Nahm, P Blinman, S Kao, H Dhillon, J Vardy. European Respiratory Review 2018 27: 180045.

    WHY DO DELAYS TO DIAGNOSIS AND TREATMENT OF LUNG CANCER OCCUR? A MIXED METHODS STUDY OF INSIGHTS FROM AUSTRALIAN CLINICIANS
    A Malalasekera, C Shunmugum, H Dhillon, P Blinman, S Kao, J Vardy. Asia-Pacific Journal of Clinical Oncology 2020; 1-10.

    HEALTH STATUS AND WELL BEING OF CANCER SURVIVORS ATTENDING THEIR FIRST APPOINTMENT AT THE SYDNEY SURVIVORSHIP CLINIC
    C Tan, J Turner, K Kerin-Ayres, S Butler,..A Warby, I Cunningham, A Malalasekera, HM Dhillon, JL Vardy

    WHAT HAPPENS TO CANCER SURVIVORS ATTENDING A STRUCTURED CANCER SURVIVORSHIP CLINIC? SYMPTOMS, QUALITY OF LIFE AND LIFESTYLE CHANGES OVER THE FIRST YEAR AT THE SYDNEY CANCER SURVIVORSHIP CENTRE CLINIC
    JL Vardy,……A.Malalasekera, C Tan. Supportive Care in Cancer 2020.

    Contact Us

    We're not around right now. But you can send us an email and we'll get back to you, asap.

    Start typing and press Enter to search